Skip to main content
Caplight Logo









ABM Therapeutics

ABM Therapeutics

Private
ShanghaiHealthcare & Life Scienceshttp://www.abmtx.com/

Last Round

Series B

Extension

May 4, 2023

Total Funding Raised

$50M

Company Overview

ABM Therapeutics is a clinical-stage biopharmaceutical company that develops small molecule targeted therapies for the treatment of brain cancer and cancer metastases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

small molecule therapytargeted cancer therapyblood-brain barrierbrain-penetrant drugsBRAF inhibitorglioblastomabrain metastasesprecision oncologyoncology drug developmentCNS oncologydrug discovery platformkinase drug discoveryclinical-stage biopharmaMEK inhibitorHPK1 inhibitorOrphan Drug DesignationFast Track Designation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ABM Therapeutics Comparables

Compare ABM Therapeutics with similar companies based on industry and business-model similarity.

ABM Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Black Diamond Therapeutics
78%
Servier
76%
Suzhou NeuPharma Co., Ltd.
75%

ABM Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionMay 4, 2023
Series BJan 4, 2022
Series AAug 7, 2020

Key People

Founding team and executive leadership

Chen Chen

Chief Executive Officer

Executive Team

ABM Therapeutics Investors

Notable investors and investment history

ABM Therapeutics investors
InvestorRounds
HighLight CapitalSeries B
Photon FundSeries B
Sincere CapitalSeries B
Jiangsu Honghui Equity Investment ManagementSeries B
Kaitai CapitalSeries A
健壹资本Series A
Baidu VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 4, 2022

    $30M round led by Photon Fund and HighLight Capital

  • Aug 7, 2020

    $20M round led by 华创资本.

ABM Therapeutics Filings

Explore SEC and related filing metadata, where available.

ABM Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ABM Therapeutics's valuation, stock price, and market status.

Is ABM a public or private company?

ABM is a private company.

What is the current stock price of ABM?

ABM is a private company with no public stock price. No recent secondary market data is available.

How much is ABM worth (valuation)?

Valuation information for ABM is not publicly available.

Can I buy ABM stock?

ABM shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ABM's last funding round?

ABM's most recent funding round was Series B Extension on May 4, 2023.

Who are the main investors in ABM?

Key investors in ABM include HighLight Capital, Photon Fund, 华创资本.

Will ABM IPO soon?

No public IPO plans have been announced for ABM.

How can I track ABM secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ABM's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShanghai
Employee Range4
Year Founded2015
Last FundingMay 4, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?